Research findings provide evidence that targeting the galectin1 protein, in combination with radiation therapy, can pave the way for future clinical trials to treat glioblastoma tumors.
Research shows that T-cell responses derived from immune system memory against 'common cold' coronaviruses enhance SARS-CoV-2 immune responses after infection and after vaccination with the Pfizer-BioNTech COVID-19 vaccine, but decrease with age.
A new blood test could help detect early signs of cancer in patients with neurofibromatosis type 1 and help monitor how well patients are responding to treatment, according to National Cancer Institute and Washington University research.
Flagship Pioneering startup Laronde has attracted a huge $440M in Series B financing, which the company will use to develop and bring its novel circular "endless" RNA therapeutics to market.
The design of cancer drugs targeting p53 gain of function mutations should take into account the role of chromosomal alterations, according to new research.
MIT engineers are developing a drug capsule technology that could allow the oral delivery of monoclonal antibodies, or other large protein-based drugs that normally have to be injected, for diseases ranging from cancer to rheumatoid arthritis.
Genome Medical will acquire telehealth specialist GeneMatters following completion of a $60 million Series C financing, propelling the company into the next phase of commercial growth and enabling it to realize its goal of genome-driven personalization of health.
Japanese scientists report a new approach where mutant DNA sequences inside cellular mitochondria can be eliminated using a bespoke chemical compound, which may lead to better treatments for mitochondrial diseases in the future.
A new AI algorithm developed by German researchers uses transfer learning to compare datasets from single-cell genomics with existing references, preserving privacy and making annotating and interpreting of new data sets very easy.
RNA expression changes in the tumor and tumor environment could at least partially explain why Black Americans have more severe and harder to treat prostate cancer than White Americans, according to new research findings.
